STOCK TITAN
  1. Home
  2. News
  3. NVRO

Nevro to Report First Quarter 2021 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021.

Management will host a conference call on May 5, 2021 to discuss first quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 6194499. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com

.

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-first-quarter-2021-financial-results-301248063.html

SOURCE Nevro Corp.

Stock NVRO logo
NEVRO CORP.

NYSE:NVRO

NVRO Rankings

#3163 Ranked by Market Cap
#4959 Ranked by Stock Gains
N/A Ranked by Dividends

NVRO Latest News

Apr 17, 2024
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
Feb 28, 2024
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Feb 21, 2024
Nevro Enters Into Cooperation Agreement With Engaged Capital
Feb 21, 2024
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Feb 1, 2024
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

NVRO Stock Data

414.13M
35.44M
3.91%
108.64%
11.54%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About NVRO

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.